Chargement en cours...
Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data
BACKGROUND: So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for gastric adenocarcinoma based on a novel analysis of “The Cancer Genome Atlas (TCGA)” database. METHOD...
Enregistré dans:
| Publié dans: | Gastric Cancer |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Singapore
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7305081/ https://ncbi.nlm.nih.gov/pubmed/32107691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-020-01045-9 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|